Integrated analysis of circulating tumor DNA (ctDNA) and circulating tumor cell (CTC) burden significantly improved differentiation between stable disease and progressive disease in treated cancer patients.
The combined liquid biopsy approach provided a more comprehensive view of tumor biology by capturing both genomic alterations (ctDNA) and intact tumor cells (CTCs) circulating in the bloodstream.
Biomarker complementarity between ctDNA and CTCs enhanced diagnostic sensitivity and detection accuracy compared with single-modality liquid biopsy methods.
ctDNA analysis enabled identification of tumor-specific genomic mutations and molecular alterations, while CTC enumeration provided insights into tumor cell dissemination and metastatic potential.
The dual biomarker strategy supports real-time monitoring of treatment response, allowing clinicians to track molecular and cellular changes during therapy.
Integrated ctDNA–CTC profiling may facilitate earlier detection of disease progression and therapeutic resistance before radiologic evidence becomes apparent.
This approach strengthens liquid biopsy–based precision oncology, enabling more informed clinical decisions and personalized treatment adaptation.
Overall, combined ctDNA and CTC analysis represents a powerful strategy for longitudinal cancer monitoring, therapy response evaluation, and optimized patient management.
Read Abstract